نتایج جستجو برای: daclatasvir
تعداد نتایج: 714 فیلتر نتایج به سال:
Objective: This study aimed to prepare and evaluate oral disintegrating tablets (ODTs) of Daclatasvir dihydrochloride (DCV) using different co-processed excipients enhance drug dissolution improve bioavailability for the treatment hepatitis C infection. Methods: Ten Daclatasvir-ODTs formulae were prepared via direct compression. The evaluated according taste masking, weight variation, thickness...
Introduction There is paucity of data on sofosubvir (SOF)-based therapy in patients on maintenance hemodialysis (MHD). The objective of this report is to describe our experience using SOF-based direct antiviral agent (DAA) therapy in MHD patients in India. Methods All patients on MHD and treated with SOF-based therapy were included in this study. Before starting treatment, viral load, genotyp...
Background. Daclatasvir and asunaprevir dual therapy is approved for the treatment of HCV genotype 1b infection in several countries. AIM To evaluate the efficacy and safety of daclatasvir and asunaprevir dual therapy in Turkish patients. MATERIAL AND METHODS Sixty-one patients with HCV genotype 1b were enrolled in the Turkish early access program. Most of the patients were in difficult-to...
AIM Hepatitis C virus (HCV) infection is a risk factor for end-stage renal disease, renal graft failure, and hemodialysis patient mortality. However, the efficacy of direct-acting antiviral therapy for HCV-infected patients with renal impairment is unclear. Additionally, the promising NS5B inhibitor sofosbuvir has not been recommended for patients with severe renal impairment. In this prospecti...
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be f...
BACKGROUND & AIMS The combination of peginterferon and ribavirin with telaprevir or boceprevir is the standard treatment of hepatitis C virus (HCV) genotype 1 infection. However, these drugs are not well tolerated because of their side effects and suboptimal virologic responses. In a phase 2a, open-label study, we examined the safety and efficacy of an interferon-free, ribavirin-free regimen of...
We report the findings of an early access program providing treatment for chronic hepatitis C virus infection (any genotype) with daclatasvir and sofosbuvir with/without ribavirin to patients with Child-Pugh class C cirrhosis or prior liver transplant recipients with recurrent hepatitis C virus infection and advanced fibrosis/cirrhosis. Patients had <12-month life expectancies per the local inv...
Background and aims. Pegylated interferon (Peg-INF) and ribavirin (RBV) based therapy is suboptimal and poorly tolerated. We evaluated the safety, tolerability and efficacy of a 24-week course of sofosbuvir plus daclatasvir without ribavirin for the treatment of hepatitis C virus (HCV) recurrence after liver transplantation (LT) in both HCV-monoinfected and human immunodeficiency virus (HIV)-H...
Background: Hepatitis C virus HCV infection is one of the main causes chronic liver disease worldwide, Egypt has highest national-level prevalence in world, Sofosbuvir/ Daclatasvir (SOF/DAC) regimen widely used to treat Egypt.
 Aims: identify predictors treatment failure with Sofosbuvir/Daclatasvir for 12 weeks Egyptian patients.
 Methodology: A retrospective cohort, we investigated 2...
Objective: To ascertain the efficacy of sofosbuvir combined with daclatasvir against hepatitis C genotype 3 infection.
 Study Design: Prospective longitudinal study.
 Place and Duration Study: Ayub Teaching Hospital, Abbottabad, Pakistan, from Nov 2018 to Jan 2020.
 Methodology: About 262 patients were treated during study. Patients symptoms associated liver failure, including as...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید